SEARCH

SEARCH BY CITATION

References

  • 1
    Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293: 20952101
  • 2
    Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst 2009; 101: 13251329
  • 3
    Thaxton CS, Loeb S, Roehl KA, Kan D, Catalona WJ. Treatment outcomes of radical prostatectomy in potential candidates for 3 published active surveillance protocols. Urology 2010; 75: 414418
  • 4
    van den Bergh RC, Roemeling S, Roobol MJ et al. Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol 2007; 52: 15601563
  • 5
    Hashimoto Y, Okamoto A, Imai A et al. Biochemical outcome of small-volume or insignificant prostate cancer treated with radical prostatectomy in Japanese population. Int J Clin Oncol 2012; 17: 119122
  • 6
    Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368374
  • 7
    Wolters T, Roobol MJ, van Leeuwen PJ et al. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 2011; 185: 121125
  • 8
    Duffield AS, Lee TK, Miyamoto H, Carter HB, Epstein JI. Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol 2009; 182: 22742278
  • 9
    Conti SL, Dall'era M, Fradet V et al. Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol 2009; 181: 16281633
  • 10
    Louie-Johnsun M, Neill M, Treurnicht K, Jarmulowicz M, Eden C. Final outcomes of patients with low-risk prostate cancer suitable for active surveillance but treated surgically. BJU Int 2009; 104: 15011504
  • 11
    Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011; 186: 18301834
  • 12
    Fradet V, Kurhanewicz J, Cowan JE et al. Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiology 2010; 256: 176183
  • 13
    Morgan VA, Riches SF, Thomas K et al. Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance. Br J Radiol 2011; 84: 3137
  • 14
    Abouassaly R, Lane BR, Jones JS. Staging saturation biopsy in patients with prostate cancer on active surveillance protocol. Urology 2008; 71: 573577
  • 15
    Ploussard G, Durand X, Xylinas E et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol 2011; 59: 422429
  • 16
    Klotz L, Zhang L, Lam A et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126131
  • 17
    van As NJ, Norman AR, Thomas K et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008; 54: 12971305
  • 18
    Soloway MS, Soloway CT, Eldefrawy A et al. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol 2010; 58: 831835
  • 19
    Tosoian JJ, Trock BJ, Landis P et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011; 29: 21852190
  • 20
    Cooperberg MR, Cowan JE, Hilton JF et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol 2011; 29: 228234
  • 21
    van den Bergh RC, Roemeling S, Roobol MJ et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2009; 55: 18
  • 22
    Soloway MS, Soloway CT, Williams S et al. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int 2008; 101: 165169
  • 23
    Krakowsky Y, Loblaw A, Klotz L. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics. J Urol 2010; 184: 131135